• Press Releases.png

    Press Releases

Prism Research Selects OmniComm Systems’ TrialOne® Suite to Automate Phase I Clinic Operations

March 05, 2013


Dr Kuno van der Post
OmniComm Systems, Inc.

Download Press Release

OmniComm’s Innovative Hosted, Turnkey Solution Expedites Implementation

Fort Lauderdale, FL, March 5, 2013 – OmniComm Systems, Inc., one of the fastest growing companies in the EDC marketplace, today announced that its TrialOne® suite of applications has been chosen by Prism Research to automate their clinical trial operations and processes within their early phase clinic. 

TrialOne® is a web-based, mobile, clinic automation solution designed specifically for early-phase research to facilitate recruitment, appointment scheduling, study building and design, screening, source data capture, sample tracking and reporting. TrialOne® offers time-based data entry and integration with bar-code scanners and printers as well as biomedical monitoring devices to automate data, sample collection and processing.  Additionally, TrialOne’s import and export features provide integration with LIM systems for lab orders and results processing as well as full SAS export capability including support of SDTM domains.

“Traditionally, implementing solutions for Phase I clinics has been difficult, time-consuming and cost prohibitive,” said Stephen Johnson, President and COO of OmniComm.  “Most offerings today do not work well for these fast-paced clinics who demand instantaneous and reliable solutions.  In the past, clinics have had to resort to localized solutions and manage the IT infrastructure internally.  Implementations took up to a year and were extremely complex and resource intensive.  With our Software-as-a-Service approach, the entire process from kickoff to production for this implementation will be less than 6 months.”

OmniComm offers a turnkey, hosted solution and a Quick Start validation package that facilitates and expedites the entire implementation process.  Clinics can centralize their installation in OmniComm’s world-class data center and back-up facilities without the costly infrastructure and overhead of additional staff and software upgrades.
Prism Clinical Research is a Phase I-IV, 52-bed, clinical trial site located in the heart of the Minneapolis / St. Paul metropolitan area that specializes in complex, phase I and phase IIA clinical trials.  In addition to healthy volunteer studies, Prism Clinical Research possesses a diverse, volunteer database of numerous disease states.

About OmniComm Systems

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

About Prism Research

Prism Clinical Research is a Twin Cities' based clinical research company committed to the advancement of improved medical knowledge and our community’s health. Prism provides, FDA approved, investigational pharmaceutical and medical device testing services on behalf of drug and device manufacturers, academic and private physicians as well as other researchers across Minnesota.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.